Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anaptysbio (ANAB) EBITDA (2016 - 2025)

Anaptysbio's EBITDA history spans 10 years, with the latest figure at $49.5 million for Q4 2025.

  • For Q4 2025, EBITDA rose 322.79% year-over-year to $49.5 million; the TTM value through Dec 2025 reached -$13.6 million, up 90.59%, while the annual FY2025 figure was -$13.6 million, 90.59% up from the prior year.
  • EBITDA reached $49.5 million in Q4 2025 per ANAB's latest filing, up from $15.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $49.5 million in Q4 2025 to a low of -$46.5 million in Q2 2024.
  • Average EBITDA over 5 years is -$25.4 million, with a median of -$34.8 million recorded in 2022.
  • Peak YoY movement for EBITDA: plummeted 6778.74% in 2022, then surged 322.79% in 2025.
  • A 5-year view of EBITDA shows it stood at -$32.8 million in 2021, then increased by 21.7% to -$25.7 million in 2022, then tumbled by 58.5% to -$40.7 million in 2023, then skyrocketed by 45.3% to -$22.2 million in 2024, then soared by 322.79% to $49.5 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's EBITDA are $49.5 million (Q4 2025), $15.2 million (Q3 2025), and -$38.8 million (Q2 2025).